Impax Says Opana Deal Didn't Delay Competition
Impax Laboratories Inc. has hit back at efforts to revive a pay-for-delay case over the opioid medication Opana ER, telling the Federal Trade Commission in a brief that the agreement it...To view the full article, register now.
Already a subscriber? Click here to view full article